BioCentury
ARTICLE | Company News

Viagene Inc., Ajinomoto Co. Inc. deal

July 10, 1995 7:00 AM UTC

VIGN received a non-exclusive license from Ajinomoto (Tokyo) for the use of the Interleukin-2 (IL-2) gene in gene therapy treatments for cancer and other diseases. Ajinomoto will receive an undisclosed license fee and royalties. The San Diego company expects to enter the clinic in 1996 with its gene therapy product that contains the IL-2 gene. ...